Abstract:Abstract Background: In humans, the β-like globin genes are encoded from a single locus comprising five globin genes (ε-, Gγ-, Aγ-, δ-, and β-globin in sequence) and their expression is under developmental control. The γ-globin genes (Gγ- and Aγ-) are expressed during fetal life and replaced by adult β-globin after birth. Mutations in the β-globin gene cause β-hemoglobinopathies such as sickle cell disease (SCD) and β-thalassemia. The clinical severity of SCD and β-thalassemia can be mitigated by elevated fetal hemoglobin (HbF) levels, which have been found in individuals with the benign hereditary persistence of fetal hemoglobin (HPFH) syndrome. Thus, reactivating the expression of γ-globin genes is an attractive treatment strategy for β-hemoglobinopathies. Reactivation of γ-globin expression by disrupting the binding of the BCL11A transcriptional repressor complex to the γ-globin gene promoter, provides a novel approach for inducing fetal hemoglobin. Methodology: The BCL11A binds a 5′-TGACCA-3′ element (spanning nucleotides −118 to −113) of globin genes using its three C-terminal Zinc fingers (Znf). The binding efficiency of Znf4, Znf5, and Znf6 was predicted by using in silico tools (SIFT, SNAP, PolyPhen-2, PANTHER, I-Mutant, PROVEAN, SNPs&GO, mCSM, and PhD-SNP), molecular dynamic simulation and homology modelling. K562 cells were electroporated with CRISPR-Cas9 targeting the BCL11A Znf4. Results: The binding energy scores illustrate that deleting Znf5 and Znf6 decreased the binding affinity by ~3.7-fold, whereas deleting Znf4 decreased the affinity by > 70-fold. Using CRISPR-Cas9 genome-editing strategy, we deleted Znf4 (260bp genomic region) within the BCL11A in K562 cell lines. Znf4 deletion resulted in a readily detectable γ-globin increase with a preferential increase in G-gamma. Conclusion: Altogether, our findings highlight the valuable insights for improving gene editing therapy strategies by either deleting Znf4 of BCL11A or the TTGACCA motif to disrupt the interaction between BCL11A and other interacting partners and the γ-globin gene promoter. Complete failure in the protein-protein interactions with functional partners and to the γ-globin gene promoter revealed that Znf4 is a suitable target for disrupting BCL11A-mediated hemoglobin switching. Citation Format: Irfan Hussain, Kainaat Mumtaz, Hammad Hassan, Afsar Ali Mian. Amelioration of hemoglobinopathies by targeted deletion of zinc finger domain within BCL11A gene using CRISPR-Cas9 technology. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4746.

CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression

Highly efficient therapeutic gene editing of human hematopoietic stem cells

Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs

CRISPR–Cas9-mediated gene editing of the BCL11A enhancer for pediatric β 0 /β 0 transfusion-dependent β-thalassemia

Innovative Transformer Base Editor (Tbe)-Mediated Editing at BCL11A Binding Motif Triggers High Level of Γ-Globin Expression with No Observable Off-Target Mutations

Detection of CRISPR/Cas9-Mediated Fetal Hemoglobin Reactivation in Erythroblasts Derived from Cord Blood-Hematopoietic Stem Cells

Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells

Combined approaches for increasing fetal hemoglobin (HbF) and de novo production of adult hemoglobin (HbA) in erythroid cells from β-thalassemia patients: treatment with HbF inducers and CRISPR-Cas9 based genome editing

Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies

Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia

CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia

Induction of therapeutic levels of HbF in genome-edited primary β0 39-thalassaemia haematopoietic stem and progenitor cells

In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice.

In Vivo HSC Gene Therapy with Base Editors Allows for Efficient Reactivation of Fetal Globin in Beta-Yac Mice

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Therapeutic base editing of human hematopoietic stem cells

Abstract 4746: Amelioration of hemoglobinopathies by targeted deletion of zinc finger domain within BCL11A gene using CRISPR-Cas9 technology

In situ correction of various β-thalassemia mutations in human hematopoietic stem cells

Enhancement of erythropoietic output by Cas9-mediated insertion of a natural variant in haematopoietic stem and progenitor cells

Safety and efficacy studies of CRISPR/Cas9 treatment of sickle cell disease in clinically relevant conditions highlights disease-specific responses

Supramolecular nanosubstrate–mediated delivery system enables CRISPR-Cas9 knockin of hemoglobin beta gene for hemoglobinopathies